Recent advances in immunotherapy of allergic rhinitis.
Lee
Chul Hee
CH
Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, 464-707, South Korea. chulhee@snu.ac.kr
Mo
Ji-Hun
JH
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000286:Administration, Sublingual; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001402:B-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology; D004247:DNA / Q000276:immunology; D003888:Desensitization, Immunologic; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D000069444:Omalizumab; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy*; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology
D000276:Adjuvants, Immunologic; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D000069444:Omalizumab; D007073:Immunoglobulin E; D004247:DNA